Abstract
Survival of untreated patients with inoperable primary liver neoplasms is approximately 75 days (1,2). Before Adriamycin, both intravenous and intra-arterial chemotherapeutic agents had very little effect upon the survival of these patients despite tumor shrinkage (3,4). Adriamycin given IV as a single agent or in combination with other drugs resulted initially in a response of 78% (5). Later studies reported response rates ranging from 9% to 44% (6–14). In 67% of patients with primary liver neoplasms, disease seems confined to the liver at the time of diagnosis, and even at autopsy disease is still confined to the liver in 44% of the patients (15). A regional approach to a disease with such dismal prognosis seems warranted. A pilot study of hepatic arterial infusion of floxuridine, Adriamycin, and mitomycin C (FUDRAM) resulted in a response rate of 66% in patients with hepatocellular carcinoma (16). We decided, therefore, to explore this treatment regimen further.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Purves LR, Bersohn I, Geddes EW: Serum alpha fetoprotein and primary cancer of the liver in man. Cancer (25): 1261–1270, 1970.
Jaffe BM, Donegan WL, Watson, S, Spratt JS: Factors influencing survival in patients with untreated hepatic metastases. Surg Gynecol Obstet (128): 1–11, 1975.
Moertel GC: Clinical management of advanced gastrointestinal cancer. Cancer (36): 675–682, 1975.
Al-Sarraf M, Go TS, Kithier K, Vaitkevicius ZK: Primary liver cancer: A review of the clinical features, blood groups, serum enzymes, therapy and survival of 65 cases. Cancer (33): 574–582, 1974.
Olweny CLM, Toya T, Katongole-Mbidde E, Mugerwa J, Kyalwazi SK, Cohen H: Treatment of hepatocellular carcinoma with adriamycin. Cancer (36) 1250–1257, 1975.
Vogel CL, Bayley AC, Brooker RJ, Anthony PP, Ziegler JL: A phase II study of adriamycin (NSC 123127) in patients with hepatocellular carcinoma from Zambia and the United States. Cancer (39): 1923–1929, 1977.
Baker LH, Saiki JH, Jones SE, Hewlett JS, Brownlee RW, Stephens RL, Vaitkevicius VK: Adriamycin and 5-Fluorouracil in the treatment of advanced hepatoma: A Southwest Oncology Group. Cancer Treat Rep (61): 1595–1597, 1977.
Falkson G, Moertel CG, Lavin P, Pretorius FJ, Carbone PP: Chemotherapy studies in primary liver cancer. A prospective randomized clinical trial. Cancer (42): 2149–2156, 1978.
Johnson PJ, Williams R, Thomas H, Sherlock S, Murray-Lyon IM: Induction of remission in hepatocellular carcinoma with doxorubicin. Lancet (1): 1006–1009, 1978.
Vilaseca J, Guardia J, Bacardi R, Monne J: Doxorubicin for liver cancer. Lancet (1)s1367 , 1978 .
Olweny CLM, Katongole-Mbidde E, Bahendeka S, Otim D, Mugerwa J, Kyalwazi SK: Further experience in treating patients with hepatocellular carcinoma in Uganda. Cancer (46): 2717–2722, 1980.
Morstyn G, Ihde DC, Eddy JLf Bunn PA, Cohen MH, Minna JD: Combination chemotherapy of hepatocellular carcinoma with doxorubicin and streptozotocin. Am J Clin Oncol (6): 547–551, 1983.
Melia WM, Johnson PJ, Williams R: Induction of remission in hepatocellular carcinoma. Cancer (51): 206–210, 1983.
Choi TK, Lee NW, Wong J: Chemotherapy for advanced hepatocellular carcinoma. Cancer (53): 401–405, 1984.
Appelqvist P: Primary carcinoma of the liver: Clinical course and therapeutic results. J Surg Oncol (21):8 7–93 r 1982.
Patt, YZ, Chuang VP, Wallace S, Benjamin RS, Fuqua R, Mavligit GM: Hepatic arterial chemotherapy and occlusion for palliation of primary hepatocellular and unknown primary neoplasms in the liver. Cancer (51): 1359–1363, 1983.
Patt, YZ, Mavligit GM, Chuang VP, Wallace S, Johnston S, Benjamin RS, Valdivieso M, Hersh, EM: Percutaneous hepatic infusion (HAI) of mitomycin C and floxuridine (FUDR): An effective treatment for metastatic colorectal carcinoma in the liver. Cancer (46): 261–265, 1980.
Patt, YZ, Chuang VP, Wallace S, Johnston S, Fuqua R, Hersh EM, Freireich EJ, Mavligit GM: The palliative roleof hepatic arterial infusion and arterial occlusion in colorectal carcinoma metastatic to the liver. Lancet (1): 349–351, 1981.
Patt, YZ, Peters RE, Chuang VP, Wallace S, Fuqua R, Mavligit GM: Effective retreatment of patients with colorectal cancer and liver metastases. Amer J Med (75): 237–240, 1983.
Kaplan EL, Meier P: Non-parametric estimation from incomplete observation. J AM Stat Assoc (53):457–481, 1958 .
Gehan EA: A generalized Wilcoxon test for comparing arbitrarily single censored samples. Biometrica (52): 203–223, 1965.
Ensminger WD, Rosowsky A, Raso V, Lewin DC, Glode M, Come S, Steele G, Frei E III: A clinical pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2’-deoxyuridine and 5-fluorouracil. Cancer Res (38): 378–3792, 1978.
Gyves J, Ensimger W, Stetson P, VanHarken D, Janis M, Cho K, Meyer S, Walker S, Gilbertson S, Niederhuber J: Clinical pharmacology of mitomycin C (Mito) by hepatic arterial (HA) infusion. Pro ASCO (2):C–97, 1983.
Garnick MB, Ensminger WD, Israel M: A clinical-pharmacological evaluation of hepatic arterial infusion of Adriamycin. Cancer Res (39): 4105–4110, 1979.
Falkson G, Mclntyre JM, Moertel CG, Johnson LA, Sherman RC: Primary liver cancer , an ECOG therapeutic trial. Cancer, in press 1984.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1984 Martinus Nijhoff Publishers, Boston
About this chapter
Cite this chapter
Patt, Y.Z., Charnsangavej, C., Soski, M. (1984). Hepatic Arterial Infusion of Floxuridine, Adriamycin, and Mitomycin C for Primary Liver Neoplasms. In: Howell, S.B. (eds) Intra-Arterial and Intracavitary Cancer Chemotherapy. Developments in Oncology, vol 26. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-3843-7_12
Download citation
DOI: https://doi.org/10.1007/978-1-4613-3843-7_12
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-3845-1
Online ISBN: 978-1-4613-3843-7
eBook Packages: Springer Book Archive